DIR 178, DIR 175, DIR 173, DIR 158, DIR 157, DIR 155, DIR 149, DIR 145, DIR 143, DIR 139, DIR 138, DIR 127, DIR 091, DIR 066 and DIR 062 annual reports.
Information on COVID vaccine clinical trial
Clinical trial with a genetically modified Vaccinia virus based treatment for solid cancerous tumours
Inadvertent dealings with genetically modified soybean
Details of OGTR monitoring and compliance activities during the quarter ended 31 March 2023.
This issue focuses on the OGTR Online Services Portal and NLRD intermittent reporting.
Commercial release of banana genetically modified for resistance to Fusarium wilt tropical race 4 (TR4)
This infographic gives a brief description of the difference between OGTR and FSANZ regulatory remits, where the OGTR conducts risk analysis and licensing for commercial cultivation, while FSANZ conducts food safety assessments, approves food for sale and sets labelling requirements.
Clinical trial of genetically modified Lactobacillus brevis for treatment of inflammatory bowel disease
Commercial supply of Qdenga, a live attenuated GM dengue vaccine